Matching-adjusted indirect comparison of guselkumab versus risankizumab in patients with moderate-to-severe plaque psoriasis: Change in baseline Psoriasis Area and Severity Index from week 4 to 40

被引：0
|
作者：
Langley, Richard G. [1 ]
Sanyal, Chiranjeev [2 ,3 ]
Situ, Aaron [3 ,4 ]
Alulis, Sarah [5 ]
Hassan, Fareen [6 ]
Peterson, Steve [7 ]
Teneralli, Rachel E. [7 ]
Lee, Jennifer [5 ]
Patel, Barkha P. [3 ]
Disher, Tim [3 ]
机构：
[1] Dalhousie Univ, Dept Med, Div Clin Dermatol & Cutaneous Sci, Halifax, NS, Canada
[2] Dalhousie Univ, Coll Pharm, Dept Community Hlth & Epidemiol, Halifax, NS, Canada
[3] CRGEVERSANA, Value & Evidence Serv, Burlington, ON, Canada
[4] Tigermed BDM, Somerset, NJ USA
[5] Janssen Cilag AS, Birkerod, Denmark
[6] Janssen Cilag Ltd, High Wycombe, England
[7] Janssen Immunol Global Commercial Strategy Org, Horsham, PA USA
来源：
JAAD INTERNATIONAL | 2024年 / 15卷
关键词：
change from baseline; guselkumab; indirect treatment comparisons; matching-adjusted indirect comparison; risankizumab; PASI;
D O I：
10.1016/j.jdin.2023.12.012
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
[No abstract available]
引用
收藏
页码：165 / 167
页数：3
相关论文
共 50 条
  • [1] MATCHING-ADJUSTED INDIRECT COMPARISON OF GUSELKUMAB VERSUS RISANKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS: CHANGE IN BASELINE PASI FROM WEEK 4-40
    Sanyal, C.
    Situ, A.
    Alulis, S.
    Hassan, F.
    Peterson, S.
    Lee, J.
    [J]. VALUE IN HEALTH, 2022, 25 (01) : S206 - S206
  • [2] COMPARATIVE EFFICACY OF GUSELKUMAB AND TILDRAKIZUMAB IN MODERATE-TO-SEVERE PLAQUE PSORIASIS: A MATCHING-ADJUSTED INDIRECT COMPARISON
    Van, Sanden S.
    Diels, J.
    Schubert, A.
    Barthelmes, J.
    [J]. VALUE IN HEALTH, 2020, 23 : S410 - S410
  • [3] Matching-adjusted indirect treatment comparison of guselkumab and ixekizumab in patients with moderate-to-severe psoriasis
    Varu, Abhishek
    Cameron, Chris
    Diels, Joris
    Hutton, Brian
    McElligott, Sean
    Schubert, Agata
    van Sanden, Suzy
    Villacorta, Reggie
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (03) : AB187 - AB187
  • [4] Matching-adjusted indirect comparison of efficacy in patients with moderate-to-severe plaque psoriasis treated with ixekizumab vs. secukinumab
    Warren, R. B.
    Brnabic, A.
    Saure, D.
    Langley, R. G.
    See, K.
    Wu, J. J.
    Schacht, A.
    Mallbris, L.
    Nast, A.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2018, 178 (05) : 1064 - 1071
  • [5] Efficacy of Brodalumab and Guselkumab in Patients with Moderate-to-Severe Plaque Psoriasis Who are Inadequate Responders to Ustekinumab: A Matching Adjusted Indirect Comparison
    Hampton, Philip
    Borg, Emma
    Hansen, Jes Birger
    Augustin, Matthias
    [J]. PSORIASIS-TARGETS AND THERAPY, 2021, 11 : 123 - 131
  • [6] Matching-Adjusted Indirect Comparison of the Long-Term Efficacy of Deucravacitinib Versus Adalimumab for Moderate to Severe Plaque Psoriasis
    April W. Armstrong
    Sang Hee Park
    Vardhaman Patel
    Malcolm Hogan
    Wei-Jhih Wang
    David Davidson
    Viktor Chirikov
    [J]. Dermatology and Therapy, 2023, 13 : 2589 - 2603
  • [7] Matching-Adjusted Indirect Comparison of the Long-Term Efficacy of Deucravacitinib Versus Adalimumab for Moderate to Severe Plaque Psoriasis
    Armstrong, April W.
    Park, Sang Hee
    Patel, Vardhaman
    Hogan, Malcolm
    Wang, Wei-Jhih
    Davidson, David
    Chirikov, Viktor
    [J]. DERMATOLOGY AND THERAPY, 2023, 13 (11) : 2589 - 2603
  • [8] Correction to: Matching-Adjusted Indirect Comparison of the Long-Term Efficacy of Deucravacitinib Versus Adalimumab for Moderate to Severe Plaque Psoriasis
    April W. Armstrong
    Sang Hee Park
    Vardhaman Patel
    Malcolm Hogan
    Wei-Jhih Wang
    David Davidson
    Viktor Chirikov
    [J]. Dermatology and Therapy, 2023, 13 : 2605 - 2607
  • [9] Indirect comparison of ixekizumab versus risankizumab for up to 12 weeks of treatment in patients with moderate-to-severe psoriasis
    Gottlieb, Alice B.
    Ramot, Yuval
    Smith, Saxon D.
    Saure, Daniel
    Schuster, Christopher
    Schacht, Alexander
    Thaci, Diamant
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB226 - AB226
  • [10] EARLY INITIATION OF GUSELKUMAB INCREASES DURATION OF COMPLETE REMISSION (PSORIASIS AREA AND SEVERITY INDEX 100) IN PATIENTS WITH MODERATE-TO-SEVERE PSORIASIS
    Moreau, R.
    Passeron, T.
    Seneschal, J.
    Rodriguez, I
    Clevy, L.
    Constantin, C.
    Dalibot, C.
    Pariente, B.
    Berkovitch, Q.
    Jullien, D.
    Leleu, H.
    [J]. VALUE IN HEALTH, 2023, 26 (12) : S164 - S164
12345